Mid-Atlantic Biotherapeutics

Mid-Atlantic BioTherapeutics is a private, clinical-stage biotech company headquartered in Rockville, Maryland, pursuing an integrated therapeutic strategy across oncology and neurology. The company's core approach combines an immunotherapy platform (IMT504) and AI-driven computational methods with newly acquired small-molecule expertise from XPose Therapeutics to target challenging disease mechanisms. MABT's pipeline includes early-stage programs for Alzheimer's, Parkinson's, ALS, rabies, and various cancers, positioning it in high-need but high-risk therapeutic areas. The acquisition of XPose represents a strategic pivot to broaden its pipeline and scientific capabilities, though the company remains pre-revenue with programs predominantly in pre-clinical or early clinical stages.

Integrated platform combining a proprietary immunotherapy platform (IMT504), AI-driven computational methods for drug discovery, and newly acquired expertise in small-molecule design targeting 'undruggable' DNA Damage Response (DDR) proteins.

Intensely competitive in both core areas. Faces large pharma and well-funded biotechs in neurology (e.g., Biogen, Eli Lilly) and oncology (e.g., AstraZeneca, Merck), particularly in the crowded DDR field. Differentiation hinges on successfully targeting historically undruggable proteins.